2021
The Dynamics of Infectious Diseases Associated With Injection Drug Use in Lawrence and Lowell, Massachusetts
Gonsalves GS, Paltiel A, Thornhill T, Iloglu S, DeMaria A, Cranston K, Klevens R, Walensky RP, Warren JL. The Dynamics of Infectious Diseases Associated With Injection Drug Use in Lawrence and Lowell, Massachusetts. Open Forum Infectious Diseases 2021, 8: ofab128. PMID: 34189158, PMCID: PMC8231383, DOI: 10.1093/ofid/ofab128.Peer-Reviewed Original ResearchInjection drug useDrug useHuman immunodeficiency virus (HIV) outbreaksInfectious diseasesSoft tissue infectionsCases of skinPublic health departmentsPoisson regression modelsInfectious complicationsTissue infectionsHIV casesDrainage proceduresFatal overdosesHealth departmentsComplicationsEarly interventionMonthsPotential outbreaksVirus outbreakSentinel SystemDiseaseRegression modelsOutbreakHIVOverdoses
2017
A Flow-Based Model of the HIV Care Continuum in the United States
Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Tang T, Hall HI, Kaplan EH. A Flow-Based Model of the HIV Care Continuum in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 548-553. PMID: 28471841, PMCID: PMC5533168, DOI: 10.1097/qai.0000000000001429.Peer-Reviewed Original ResearchConceptsViral suppressionAntiretroviral therapyHIV careNorth American AIDS Cohort CollaborationProportion of HIVHIV care continuumCohort CollaborationHIV diagnosisAntiretroviral treatmentVirological dataCare continuumFlow of patientsDisease controlPatientsCareAverage timeHIVTherapyLaboratory resultsMonthsSuppressionYearsDiagnosisIndividualsPrevention
2016
Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa
Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLOS ONE 2016, 11: e0165614. PMID: 27906986, PMCID: PMC5131994, DOI: 10.1371/journal.pone.0165614.Peer-Reviewed Original ResearchConceptsTB/HIVTB/HIV controlHIV screeningHIV controlRural South AfricaLife yearsMonths of IPTMost life yearsHigh-incidence settingsWidespread prevalenceCost-effectiveness resultsProbabilistic sensitivity analysesHIV transmissionHigh burdenTreatment coverageUnknown patientsHIVHealthcare accessDrug resistanceActive casesMonthsLifetime usePatientsYearsScreening
2004
A therapeutic HIV vaccine: how good is good enough?
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine 2004, 22: 4044-4053. PMID: 15364455, DOI: 10.1016/j.vaccine.2004.03.059.Peer-Reviewed Original Research